Rinn Pharma & Biopharma has a strengthened position on the international research scene, with seven of its researchers named among the world’s top 2% of scientists in the 2026 Stanford-Elsevier ranking.
The prestigious list recognises the world’s most influential researchers based on standardised citation indicators derived from Scopus data. It includes researchers whose scientific contributions rank among the top 2% within their respective fields, reflecting the global impact and influence of their published research.
The ranking is based on data from the global Scopus database, and it assesses researchers according to several indicators of scientific impact, including citations, the h-index, and the quality of scientific publications based on the impact factors of the journals in which they are published.
The seven researchers recognised in the 2026 edition are:
- Professor Damien Thompson, UL
- Professor James Gleeson, UL
- Professor David Brayden, UCD
- Professor Marcus Baumann, UCD
- Professor Jonathan Bones, NIBRT
- Professor Kevin Kavanagh, MU
- Associate Professor Rob Elmes, MU
This recognition is a powerful testament to the strength, depth and international impact of research within Rinn Pharma & Biopharma. The inclusion of seven researchers from across its university and industry partner network highlights the centre’s sustained commitment to excellence in pharmaceutical and biopharmaceutical research, innovation and talent development.
Spanning areas including drug delivery, advanced therapeutics, continuous manufacturing, biopharmaceutical analysis, biomaterials and translational healthcare solutions, the work of these researchers is helping to address some of the most significant challenges facing the global life sciences sector. Their achievements reinforce Rinn Pharma & Biopharma’s position as a leading research centre, driving scientific discovery, fostering collaboration across academia and industry, and delivering innovations that can improve patient outcomes worldwide.
As the centre continues to expand its research portfolio and international partnerships, this recognition further reflects the calibre of expertise within Rinn Pharma & Biopharma and its growing contribution to Ireland’s reputation as a global hub for pharmaceutical and biopharmaceutical research.




